APOBEC3B and APOBEC Mutational Signature As Potential Predictive Markers for Immunotherapy Response in Non-small Cell Lung Cancer

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2018 Apr 27

PMID 29695832

Citations 134

Authors

Shixiang Wang

Mingming Jia

Zaoke He

Xue-Song Liu

Affiliations

Soon will be listed here.

Abstract

Non-small cell lung cancer (NSCLC) is known to carry heavy mutation load. Besides smoking, cytidine deaminase APOBEC3B plays a key role in the mutation process of NSCLC. APOBEC3B is also reported to be upregulated and predicts bad prognosis in NSCLC. However, targeting APOBEC3B high NSCLC is still a big challenge. Here we show that APOBEC3B upregulation is significantly associated with immune gene expression, and APOBEC3B expression positively correlates with known immunotherapy response biomarkers, including: PD-L1 expression and T-cell infiltration in NSCLC. Importantly, APOBEC mutational signature is specifically enriched in NSCLC patients with durable clinical benefit after immunotherapy and APOBEC mutation count can be better than total mutation in predicting immunotherapy response. In together, this work provides evidence that APOBEC3B upregulation and APOBEC mutation count can be used as novel predictive markers in guiding NSCLC checkpoint blockade immunotherapy.

Citing Articles

Comprehensive genetic variant analysis reveals combination of KRAS and LRP1B as a predictive biomarker of response to immunotherapy in patients with non-small cell lung cancer.

Eklund E, Svensson J, Naslund L, Yhr M, Sayin S, Wiel C J Exp Clin Cancer Res. 2025; 44(1):75.

PMID: 40011914 PMC: 11866712. DOI: 10.1186/s13046-025-03342-6.

Viral infection, APOBEC3 dysregulation, and cancer.

Lehle J, Soleimanpour M, Mokhtari S, Ebrahimi D Front Genet. 2025; 15:1489324.

PMID: 39764440 PMC: 11701051. DOI: 10.3389/fgene.2024.1489324.

Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer.

Qiu M, Bai Y, Wang J, Gu K, Yang M, He Y Signal Transduct Target Ther. 2024; 9(1):349.

PMID: 39676137 PMC: 11647033. DOI: 10.1038/s41392-024-02063-0.

Somatic mutational landscape reveals mutational signatures and significantly mutated genes of cancer immunotherapeutic outcome and sex disparities.

Li Y, Wang Q, Gao X, Zheng J, Zhang W, Ren Y Front Immunol. 2024; 15:1423796.

PMID: 39555056 PMC: 11563811. DOI: 10.3389/fimmu.2024.1423796.

Apolipoprotein-B mRNA-editing complex 3B could be a new potential therapeutic target in endometriosis.

Vu T, Nakamura K, Shigeyasu K, Kashino C, Okamoto K, Kubo K Sci Rep. 2024; 14(1):24968.

PMID: 39443671 PMC: 11499600. DOI: 10.1038/s41598-024-76589-2.

References

Herbst R, Soria J, Kowanetz M, Fine G, Hamid O, Gordon M . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515(7528):563-7. PMC: 4836193. DOI: 10.1038/nature14011. View

Sasaki H, Suzuki A, Tatematsu T, Shitara M, Hikosaka Y, Okuda K . gene overexpression in non-small-cell lung cancer. Biomed Rep. 2014; 2(3):392-395. PMC: 3990218. DOI: 10.3892/br.2014.256. View

Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

Shi J, Hua X, Zhu B, Ravichandran S, Wang M, Nguyen C . Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study. PLoS Med. 2016; 13(12):e1002162. PMC: 5140047. DOI: 10.1371/journal.pmed.1002162. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Schabath M, Welsh E, Fulp W, Chen L, Teer J, Thompson Z . Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene. 2015; 35(24):3209-16. PMC: 4837098. DOI: 10.1038/onc.2015.375. View

Burns M, Lackey L, Carpenter M, Rathore A, Land A, Leonard B . APOBEC3B is an enzymatic source of mutation in breast cancer. Nature. 2013; 494(7437):366-70. PMC: 3907282. DOI: 10.1038/nature11881. View

Smid M, Rodriguez-Gonzalez F, Sieuwerts A, Salgado R, Prager-van der Smissen W, van der Vlugt-Daane M . Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nat Commun. 2016; 7:12910. PMC: 5052682. DOI: 10.1038/ncomms12910. View

Robert C, Ribas A, Wolchok J, Hodi F, Hamid O, Kefford R . Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014; 384(9948):1109-17. DOI: 10.1016/S0140-6736(14)60958-2. View

10.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

11.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

12.

Cescon D, Haibe-Kains B . DNA replication stress: a source of APOBEC3B expression in breast cancer. Genome Biol. 2016; 17(1):202. PMC: 5045630. DOI: 10.1186/s13059-016-1069-y. View

13.

Swanton C, McGranahan N, Starrett G, Harris R . APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. Cancer Discov. 2015; 5(7):704-12. PMC: 4497973. DOI: 10.1158/2159-8290.CD-15-0344. View

14.

Shukuya T, Carbone D . Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer. J Thorac Oncol. 2016; 11(7):976-88. PMC: 7179759. DOI: 10.1016/j.jtho.2016.02.015. View

15.

Kim J, Mouw K, Polak P, Braunstein L, Kamburov A, Kwiatkowski D . Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet. 2016; 48(6):600-606. PMC: 4936490. DOI: 10.1038/ng.3557. View

16.

Boichard A, Tsigelny I, Kurzrock R . High expression of PD-1 ligands is associated with mutational signature and APOBEC3 alterations. Oncoimmunology. 2017; 6(3):e1284719. PMC: 5384346. DOI: 10.1080/2162402X.2017.1284719. View

17.

Dong Z, Zhong W, Zhang X, Su J, Xie Z, Liu S . Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017; 23(12):3012-3024. DOI: 10.1158/1078-0432.CCR-16-2554. View

18.

Li B, Severson E, Pignon J, Zhao H, Li T, Novak J . Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016; 17(1):174. PMC: 4993001. DOI: 10.1186/s13059-016-1028-7. View

19.

Travis W . Pathology of lung cancer. Clin Chest Med. 2002; 23(1):65-81, viii. DOI: 10.1016/s0272-5231(03)00061-3. View

20.

Middlebrooks C, Rouf Banday A, Matsuda K, Udquim K, Onabajo O, Paquin A . Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. Nat Genet. 2016; 48(11):1330-1338. PMC: 6583788. DOI: 10.1038/ng.3670. View